Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.4.1333

Resveratrol Exerts Differential Effects in Vitro and in Vivo against Ovarian Cancer Cells  

Stakleff, Kimberly Sloan (Kenneth Calhoun Research Laboratory, Akron General Medical Center)
Sloan, Tricia (Kenneth Calhoun Research Laboratory, Akron General Medical Center)
Blanco, Denise (Kenneth Calhoun Research Laboratory, Akron General Medical Center)
Marcanthony, Sharon (Department of Obstetrics and Gynecology, Akron General Medical Center)
Booth, Tristan D. (Clinical and Innovative Development, Pharmascience, Inc.)
Bishayee, Anupam (Department of Pharmaceutical and Administrative Sciences, School of Pharmacy, American University of Health Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.4, 2012 , pp. 1333-1340 More about this Journal
Abstract
Epithelial ovarian cancer represents the most lethal gynecological cancer, and the high mortality rate makes this malignancy a major health concern. Poor prognosis results from an inability to detect ovarian cancers at an early, curable stage, as well as from the lack of an effective therapy. Thus, effective and novel strategies for prevention and treatment with non-toxic agents merit serious consideration. Resveratrol, obtained from grapes, berries, peanuts and red wine, has been shown to have a potent growth-inhibitory effect against various human cancer cells as well as in in vivo preclinical cancer models. The objective here was to evaluate potential antitumor effects of resveratrol in both in vitro and in vivo NuTu-19 ovarian cancer models. In vitro an invasion assay was performed. After 48 h, the numbers of viable cells that invaded the extracellular matrix layer were reduced by 94% with resveratrol in comparison to control. For the in vivo anti-tumor assessment, 10 rats were injected with NuTu-19 cells into the ovarian bursa. Thereafter, half were provided with a diet mixed with a dose of 100 mg resveratrol/kg body weight/day for 28 days. Following sacrifice, anticancer effects were assessed by histological evaluation of ovarian as well as surrounding tissues, and immunohistochemical detection of cell proliferation and apoptosis, but there were no observable differences between the control and resveratrol-treated groups for any of the biological endpoints. While resveratrol is effective in suppressing the in vitro cellular invasion of NuTu-19 ovarian cancer cells, these effects do not appear to impact on in vivo NuTu-19 ovarian cancers in rats.
Keywords
Resveratrol; NuTu-19 cells; ovarian cancer; anti-invasion effects; chemoprevention;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Aalto ML, Collan Y (1986). Periodic acid-Schiff stain as a prognostic indicator in serous and mucinous ovarian tumors. Int J Gynaecol Obstet, 24, 27-34.   DOI
2 Aggarwal BB, Bhardwaj A, Aggarwal RS, et al (2004). Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res, 24, 2783-40.
3 Athar M, Back JH, Kopelovich L, Bickers DR, Kim Al (2009). Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys, 486, 95-102.   DOI
4 Banerjee S, Bueso Ramos C, Aggarwal BB (2002). Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor- ${\kappa}B$, cycloxygenase 2, and matrix metalloprotease 9. Cancer Res, 62, 4945-54.
5 Becher OJ, Holland EC (2006). Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res, 66, 3355-9.   DOI
6 Bishayee A (2009). Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res, 2, 409-18.   DOI   ScienceOn
7 Bishayee A, Dhir N (2009). Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem-Biol Interact, 179, 131-44.   DOI   ScienceOn
8 Bishayee A (2012). Current advances in cancer prevention and treatment by natural products. Curr Pharm Biotechnol, 13, 115-6.   DOI
9 Bjorklund M, Roos J, Gogvadze V, Shoshan M (2011). Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low dose-dose platinum treatment. Cancer Chemother Pharmacol, 68, 1459-67.   DOI
10 Bove K, Lincoln DW, Tsan MF (2001). Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun, 291, 1001-5.
11 Brard L, Granai CO, Swamy N (2006). Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecol Oncol, 100, 116-27.   DOI   ScienceOn
12 Brewer MA, Johnson K, Follen M, Gershenson D, Bast R, Jr (2003). Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res, 9, 20-30.
13 Cao Z, Fang J, Xia C, Shi X, Jiang BH (2004). trans-3,4,5'- Trihydroxystibene inhibits hypoxia-inducible factor 1$\alpha$ and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res, 10, 5253-63.   DOI
14 Crowell JA, Korytko PJ, Morrissey Rl, Booth TD, Levine BS (2004). Resveratrol-associated renal toxicity. Toxicol Sci, 82, 614-9.   DOI
15 Delmas D, Solary E, Latruffe N (2011). Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. Curr Med Chem, 18, 1100-21.   DOI
16 Dennis T, Fanous M, Mousa S (2009). Natural products for chemopreventive and adjunctive therapy in oncologic disease. Nutr Cancer, 61, 587-97.   DOI
17 Feki A, Jefford CE, Berardi P, et al (2005). BARD1 induces apoptosis by catalyzing phosphorylation of p53 by DNAdamage response kinase. Oncogene, 24, 3726-37.   DOI
18 Fremont L (2000). Biological effects of resveratrol. Life Sci, 66, 663-73.   DOI   ScienceOn
19 Gescher AJ, Steward WP (2003). Relationship between mechanisms, bioavailability, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev, 12, 953-7.
20 Gullett NP, Ruhul Amin AR, Bayraktar S, et al. (2010) Cancer prevention with natural compounds. Semin Oncol, 37, 258-81.   DOI
21 Guo L, Peng Y, Yao J, (2010). Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice. Cancer Biother Radiopharm, 25, 471-7.   DOI
22 Harikumar KB, kunnumakkara AB, Sethi G, et al. (2010) Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer, 127, 257-68.
23 Harper CE, patel BB, Wang J, et al (2007). Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis, 28, 1946-53.   DOI   ScienceOn
24 Hebbar V, Shen G, Hu R, et al. (2005) Toxicogenomics of resveratrol in rat liver. Life Sci, 76, 2299-314.   DOI   ScienceOn
25 Hoekstra A, Rodriguez GC (2009). Chemoprevention of ovarian cancer. Cancer Treat Res, 149, 3-34.   DOI
26 Hsu SM, Raine L, Fanger H (1981). Use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase techniques: a comparison between (ABC) and unlabeled antibody (PAP) procedures. J Histochem Cytochem, 29, 577-80.   DOI
27 Jang M, Cai L, Udeani GO, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218-20.   DOI   ScienceOn
28 Kueck A, Opipari AW, Griffith KA, et al. (2007) Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol Oncol, 107, 450-7.   DOI
29 Kundu JK, Surh YJ (2008). Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett, 269, 243-61.   DOI
30 Lee MH, Choi BY, Kundu JK, et al (2009). Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res, 69, 7449-58.   DOI
31 Li ZG, Hong T, Shimada Y, et al (2002). Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis, 23, 1531-6.   DOI   ScienceOn
32 Lin C, Crawford DR, Lin S, et al. (2011) Inducible COX- 2 dependent apoptosis in human ovarian cancer cells. Carcinogenesis, 32, 19-26.   DOI
33 Marimuthu P, Kaur K, Kandalam U, et al. (2011). Treatment of ovarian cancer cells with nutlin-3 and resveratrol combination leads to apoptosis via caspase activation. J Med Food, 14, 46-52.   DOI
34 Medvetz DA, Stakleff KD, Schreiber T, et al. (2007) Ovarian cancer activity of cyclic amine and thiaether metal complexes. J Med Chem, 50, 1703-6.   DOI
35 Mills GB (2002). Mechanisms underlying chemoprevention of ovarian cancer. Clin Cancer Res, 8, 7-10.
36 NIH Consensus Development Panel on Ovarian Cancer (1995). Ovarian cancer: screening, treatment and follow-up. J Am Med Assoc, 273, 491-7.   DOI
37 Niles RM, Cook CP, Meadows GG, et al. (2006). Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr, 136, 2542-6.
38 Niles RM, Mcfarland M, Weimer MB, et al. (2003) Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett, 190, 157-63.   DOI   ScienceOn
39 Opipari JR, AW, Tan L, et al (2004). Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res, 64, 696-703.   DOI   ScienceOn
40 Park SY, Jeong KJ, Lee J, et al. (2007) Hypoxia enhances, LPAinduced HIF-$1{\alpha}$ and VEGF expression: their inhibition by resveratrol. Cancer Lett, 258, 63-9.   DOI
41 Raj MHG, Abd Elmageed ZY, Zhou J, et al (2008). Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells. Gynecol Oncol, 110, 432-8.   DOI
42 Rezk YA, Balulad SS, Keller RS, Bennett JA (2006). Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic can cell lines and in rodent heart. Am J Obstet Gynecol, 194, 23-6.   DOI
43 Rose GS, Toco LM, Granger GA, et al (1996) Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol, 175, 593-9.   DOI
44 Sankaranarayanan R, Ferlay J (2006). Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol, 20, 207-25.   DOI
45 Schneider Y, Duranton B, Gosse F, et al (2001) Resveratrol inhibits intestinal tumorigenesis and modulates host-defenserelated gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer, 39, 102-7.   DOI
46 Schumacher JJ, Dings RPM, Costin J, et al (2007). Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res, 67, 3683-90.   DOI
47 Sengottuvelan M, Viswanathan P, Nalini N (2006). Chemopreventive effect of trans-resveratrol - a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis, 27, 1038-46.   DOI   ScienceOn
48 Shukla Y, Singh R (2011). Resveratrol and cellular mechanisms of cancer prevention. Ann NY Acad Sci, 1215, 1-8.   DOI
49 Siegel R, Naishadham, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.   DOI   ScienceOn
50 Sloan Stakleff KD, Rouse AG, Ryan AP, Haller NA, Von Gruenigen VE (2005). A novel early-stage orthotopic model for ovarian cancer in the Fischer 344 rat. Int J Gynecol Cancer, 15, 246-54.   DOI
51 Sloan Stakleff KD, Von Gruenigen VE (2003). Rodent models for ovarian cancer research. Int J Gynecol Cancer, 13, 405-12.   DOI
52 Smith ER, Daly MB, Xu XX (2004). A mechanism for cox-2 inhibitor anti-inflammatory activity in chemoprevention of epithelial cancers. Cancer Epidem Biomarkers Prev, 13, 144-5.   DOI
53 Stan SD, Kar S, Stoner GD, Singh SV (2008). Bioactive food components and cancer risk reduction. J Cell Biochem, 104, 339-56.   DOI   ScienceOn
54 Subbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ (1997). Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med, 216, 201-10.   DOI
55 Subramanian L, Youssef S, Bhattacharya S, et al. (2010) Resveratrol: challenges in translation to the clinic - a critical discussion. Clin Cancer Res, 16, 5942-8.   DOI
56 Teicher BA (2006). Tumor models for efficacy determination. Mol Cancer Ther, 5, 2435-43.   DOI
57 Tessitore L, Davit A, Sarotto I, Caderni G (2000). Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21 (CIP) expression. Carcinogenesis, 21, 1619-22.   DOI   ScienceOn
58 Tyagi A, Singh RP, Agarwal C, Siriwardana S, Sciafani RA (2005). Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis, 26, 1978-87.   DOI
59 Visintin I, Feng A, Longton G, et al (2008). Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res, 14, 1065-72.   DOI   ScienceOn
60 Weng CJ, Yen GC (2012). Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. Cancer Treat Rev, 38, 76-87.   DOI
61 Yang SH, Kim JS, Oh TJ, et al (2003) Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. Int J Oncol, 22, 741-50.
62 Zhou H-B, Chen J-J, Wang W-X, Cai J-T, Du Q (2005). Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol, 11, 280-4.   DOI